Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Andrew Haydon"'
Autor:
Michael Millward, V. Atkinson, Sandip Pravin Patel, Christoph Hoeller, Christian U. Blank, Andrew Haydon, Alexander N. Shoushtari, Reinhard Dummer, Alexander M. Menzies, James Larkin, Carina N. Owen, Arissa Young, Maartje W. Rohaan, Dharmisha Chauhan, Shahneen Sandhu, Douglas B. Johnson, J. Mangana, Georgina V. Long, D. Palmieri, Matteo S. Carlino, Serigne Lo, Muhammad A. Khattak, Farzana Y Zaman, Peter Hersey, Belinda Lee
Publikováno v:
Ann Oncol
Background: Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%-30% of patients recur within 1 year. This study describes the pattern of recurrence,
Autor:
Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan
Publikováno v:
Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38, 33, pp. 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38, 33, pp. 3925-3936
PURPOSE We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. On the basis of
Autor:
Matteo S. Carlino, Andrew Haydon, Afaf Abed, Prachi Bhave, Megan Lyle, Victoria Atkinson, Georgina V. Long, Muhammad A. Khattak, Rebecca N. Johnson, Alison Weppler, Shahneen Sandhu, Alexander M. Menzies, Geoffrey David Peters
9571 Background: Adjuvant anti-PD1 therapy reduces the risk of recurrence in resected stage III/IV melanoma and is now standard care. Limited data exist beyond registration trials. We sought to explore the use of adjuvant immunotherapy in routine cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c39ca338aa6c845c716fe6aa79ffb2e
https://hdl.handle.net/2123/25652
https://hdl.handle.net/2123/25652
Autor:
Marisa Palmeri, Amelia Sawyers, Suthee Rapisuwon, Hui Yeohc, Rebecca N. Johnson, Matteo S. Carlino, Douglas B. Johnson, Alexander M. Menzies, Ryan J. Sullivan, Iman Osman, Andrew Haydon, James R. Patrinely, Maya Dimitrova, Elizabeth J. Davis, Aleigha Lawless, Prachi Bhave, Georgina V. Long, Janice M. Mehnert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Anti-programmed death-1 (anti-PD-1) therapies have improved long-term survival across many advanced cancers. However, chronic immune-related adverse events (irAEs) are not well-defined. We sought to determine the incidence, time-course, sp
Autor:
Dirk Schadendorf, Caroline Dutriaux, Caroline Robert, Reinhard Dummer, John M. Kirkwood, Marta Nyakas, Mario Mandalà, Laurent Mortier, Axel Hauschild, Kohinoor Dasgupta, Monique Tan, Eduard Gasal, James Larkin, Jacob Schachter, Vanna Chiarion Sileni, Andrew Haydon, Victoria Atkinson, Mario Santinami, Georgina V. Long
10001 Background: Previous results of the COMBI-AD trial (NCT01682083) showed a significant relapse-free survival (RFS) benefit with 12 mo of adjuvant D+T vs placebo (PBO) in pts with high-risk resected stage III BRAF V600E/K–mutant melanoma. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f486f97df79593e3e9abb490624153c0
Autor:
John M. Kirkwood, Mario Santinami, Tomas Haas, C. Robert, J.M.G. Larkin, Monique Tan, C. Dutriaux, Dirk Schadendorf, Laurent Mortier, Georgina V. Long, Jacob Schachter, Mike Lau, Axel Hauschild, Hiya Banerjee, Andrew Haydon, Reinhard Dummer, Victoria Atkinson, Mario Mandalà, Marta Nyakas, V. Chiarion Sileni
Publikováno v:
Annals of Oncology. 31:S743-S744
Autor:
Jacob Schachter, Dirk Schadendorf, Eduard Gasal, Laurent Mortier, Marta Nyakas, Egbert de Jong, Caroline Dutriaux, Reinhard Dummer, Mario Santinami, Georgina V. Long, John M. Kirkwood, Mario Mandalà, Victoria Atkinson, Vanna Chiarion-Sileni, Andrew Haydon, Caroline Robert, Christine-Elke Ortmann, James Larkin, Richard F. Kefford, Axel Hauschild
9582 Background: In the COMBI-AD trial (NCT01682083), 12 mo of adjuvant D+T led to significant improvement of RFS vs PBO (hazard ratio [HR], 0.47; P < .001) in pts with resected BRAF V600–mutant stage III melanoma; 3- and 4-year RFS rates were 59%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42511b4b46cd8c4fde9d100d74a0872
Autor:
John M. Kirkwood, Monique Tan, Caroline Dutriaux, James E. Larkin, Dirk Schadendorf, Vanna Chiarion Sileni, Reinhard Dummer, Laurent Mortier, Georgina V. Long, Andrew Haydon, Mario Santinami, Mike Lau, Jacob Schachter, Caroline Robert, Axel Hauschild, Victoria Atkinson, Tomas Haas, Hiya Banerjee, Mario Mandalà, Marta Nyakas
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:s2
not available.
Autor:
Andrew Haydon, Marta Nyakas, James Larkin, Richard F. Kefford, Reinhard Dummer, Egbert de Jong, Dirk Schadendorf, V. Chiarion-Sileni, Caroline Robert, Christine-Elke Ortmann, John M. Kirkwood, Axel Hauschild, Victoria Atkinson, Mario Santinami, Caroline Dutriaux, Edward Gasal, Georgina V. Long, Mario Mandalà, Jacob Schachter, Laurent Mortier
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 3:S53
not available.
Publikováno v:
Melanoma Management
There is a global increase in the incidence of melanoma, with approximately 300,000 new cases in 2018 worldwide, according to statistics from the International Agency for Research on Cancer. With this rising incidence, it is important to optimize tre